Roivant Sciences is trading at $37.56, up 7.56%, as its recent announcements are the clearest explanation for pre-market strength. - The company announced positive Phase 3 CLARITY program results for brepocitinib in non-infectious uveitis (NIU), meeting the primary endpoint for both CLARITY-1 and CLARITY-2 studies. - Biotech-sector strength may also be supportive.